7:50 am Breakfast & Registration Opens

8:50 am Chair’s Opening Remarks

DELVING INTO THE EVOLUTION OF PARP & ATR IN THE PAST YEAR: A REVIEW OF PARP AS MORE AGENTS ARE APPROVED & A DEEP DIVE INTO ATR POTENTIAL & PROGRESSION

9:00 am Revisiting & Refreshing DDR Inhibitor Successes & Failures by Laying out the Spectrum of Old & New Targets & Evaluating What Has Worked Well So Far

9:30 am Exploring a Novel Dual PARP-HDAC Inhibitor for the Treatment of Ewing Sarcoma

  • Mads Daugaard President & Chief Scientific Officer, Rakovina Therapeutics

Synopsis

  • kt-3000 series compounds exhibit dual PARP1/2 and HDAC inhibitor activity
  • Co-inhibition of PARP1/2 and HDACs amplifies DNA damage and cytotoxicity
  • Ewing sarcoma cells are highly sensitive to combined PARP and HDAC inhibition

10:00 am ATR: The Target of The Year – How Has this Target Progressed in 2022 & What Are the Current Challenges Faced Clinically

Synopsis

  • EMD Serono unveiled its new oral ATR inhibitor (M1774) with best-in-class potential
  • The search for BM-defined populations sufficient to support monotherapy registration continues
  • While there have been setbacks for chemotherapy-ATRi combinations, combinations with ICI look increasingly promising

10:30 am Speed Networking

Synopsis

A session dedicated to taking advantage of face-to-face networking time. An exciting opportunity to get an understanding of who else is overcoming similar challenges within the DDR space.

ANALYZING HOW INHIBITION OF THE DDR PATHWAY AFFECTS THE IMMUNE MICROENVIRONMENT

11:30 am Combining Inhibitors of the DNA Damage Response Pathway with Immunotherapies to Treat Cancer

Synopsis

  • The multiple interfaces between the DDR and the immune response
  • PARP inhibitor immune priming in BRCA deficient cancers
  • The link between ATR inhibition, replication stress and the ability to overcome immunotherapy resistance

12:30 pm Effects of Polymerase Theta Inhibition On the DDR-Deficient Immune Microenvironment

  • Geoffrey Shapiro Director, Early Drug Development Center, Dana-Farber Cancer Institute

Synopsis

  • What pathways drive immune cell infiltration following polymerase theta inhibition?
  • Is an immune response required for maximal efficacy of polymerase theta inhibitors?
  • How can polymerase theta-induced immune responses be augmented further to improve anti-tumor efficacy?

1:00 pm Panel Discussion: DDR Inhibitors & the Immune Response Interface

  • Mark O’Connor Chief Scientist, Early Oncology Discovery, AstraZeneca
  • Geoffrey Shapiro Director, Early Drug Development Center, Dana-Farber Cancer Institute

Synopsis

  • DNA damage checkpoint activation, inducing the expression of antimicrobial peptides and activating immune cell receptor ligands: what are the ways DDRis impact these immune responses
  • Which pathways within DDR are involved in immune signalling?
  • DNA damage and chronic inflammation: what is the link?

1:30 pm Lunch & Networking

ADDRESSING RESISTANCE WITH NEXT GENERATION TARGETS: DRUG DEVELOPMENT & CLINICAL TRIALS OF FAMILIAR TARGETS

2:30 pm Reviewing the Renaissance of WEE1 Inhibitors; an Old Target with a Lot of New Potential

  • Sui Xiong Cai Senior Vice President & Chief Technology Officer Oncology, IMPACT Therapeutics

Synopsis

  • The uprise of WEE1 inhibitor and its impacts
  • Designing of WEE1 inhibitors
  • Recent WEE1 inhibitor clinical data

3:00 pm Next Generation DDR/Synthetic Lethality Targets: Mining DNA Metabolism for Gold

  • Jon Hollick Managing Director & Head of Research, Breakpoint Therapeutics

Synopsis

  • Approaches to drug discovery
  • Overview of Polymerase theta as a tumour selective drug target
  • Exploiting cancer replication stress: spotlight on WRN helicase

LOOKING TO THE FUTURE & NEXT GENERATION TARGETS: EXPLORING NOVEL TARGETS ON THE HORIZON & DISCUSSING THEIR POTENTIAL AS MONOTHERAPY AGENTS

3:30 pm Session Reserved for Promega

Synopsis

4:00 pm Exploiting DNA Repair Defects via Direct DNA Modification – A New Paradigm in Oncology Drug Development

Synopsis

  • Overview of DNA modifiers (DMs) and how they can be engineered to exploit DDR defects
  • Strategies to evade known drug resistance pathways using DMs
  • Potential for combination therapies with DMs

4:30 pm A New Generation of DDR Targeting Drugs: DNA Decoy Agonists of DNAPK & PARP1

  • Wael Jdey Head of In Vitro Oncology Research & Innovation Group, Onxeo

Synopsis

  • The DDR pathway is made up of well-orchestrated machinery, with redundant pathways that could take over when one enzyme/pathway is inhibited commonly leading to acquired resistance to small molecules inhibitors
  • Onxeo developed a cutting-edge new technology to trap DDR proteins and abrogate the DNA repair machinery to trap and hyperactivate DDR enzymes, inducing a false damage signaling in tumor cells
  • These Decoy Agonists are under clinical or preclinical investigations

5:00 pm Panel Discussion: How Are Newer Targets Being Validated to Move Towards Clinical Trials?

Synopsis

  • What is the rationale behind selecting novel targets for research?
  • How do these targets differ from previous projects?
  • What do these new targets offer to existing drug development projects?

5:30 pm Chair’s Closing Remarks

5:35 pm Scientific Poster Session

Synopsis

After the formal presentations have finished for the afternoon, the learning and networking carries on. The Poster Session allows you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships. During this session, scientific posters will be presented on the latest advancements in the DDR field.

6:30 pm End of Conference Day One